Complement C5 inhibition in generalized myasthenia gravis is associated with improved survival and increased cardiovascular risk - PubMed
3 hours ago
- #myasthenia gravis
- #complement C5 inhibition
- #cardiovascular risk
- C5 inhibitors improve survival but increase cardiovascular and thromboembolic risk in generalized myasthenia gravis.
- Compared to untreated controls, C5 inhibition raises risks of acute kidney injury and thrombotic disorders.
- Ravulizumab shows lower major adverse cardiovascular events risk than eculizumab, indicating class heterogeneity.